Four years in, Sana gets first FDA go-ahead to bring cancer treatment into the clinic
Four years after its launch, Seattle-based company Sana Biotechnology announced FDA approval to start clinical trials for its allogeneic CAR-T cell therapy treatment.
The SC291 therapy targets the antigen CD19 in patients with B-cell lymphoma and leukemia to evade the immune system and assist cell therapy in producing a durable response. Sana expects data from the trial later this year and plans to file a second IND for a similar CAR-T treatment in 2023.
“Insights from this study will better inform our opportunities across the broader platform, both for CAR T cells and for programs outside of cancer such as our pancreatic islet cell therapy for patients with type 1 diabetes,” said president and CEO Steve Harr.